Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HLS Therapeutics Inc ( (TSE:HLS) ) has provided an announcement.
HLS Therapeutics Inc. has announced a new credit agreement with National Bank of Canada, replacing its previous facility with JP Morgan Chase Bank. The new CAD $107 million facility, which includes a CAD $79 million term loan, provides enhanced financial flexibility and reduces foreign exchange exposure. The agreement reflects improved terms with lower interest rates, benefiting the company’s cash flow and supporting its strategic priorities like share buybacks and portfolio expansion.
The most recent analyst rating on (TSE:HLS) stock is a Buy with a C$9.50 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.
Spark’s Take on TSE:HLS Stock
According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.
HLS Therapeutics Inc’s overall stock score is driven by strong corporate events and technical analysis, indicating positive momentum and strategic growth. However, financial performance and valuation concerns, particularly due to persistent net losses and a negative P/E ratio, weigh down the score. Addressing profitability issues is crucial for improving the stock’s attractiveness.
To see Spark’s full report on TSE:HLS stock, click here.
More about HLS Therapeutics Inc
HLS Therapeutics Inc. is a pharmaceutical company established in 2015, focusing on the acquisition and commercialization of late-stage development and established branded pharmaceutical products in North America. The company targets the central nervous system and cardiovascular therapeutic areas, leveraging the expertise of its seasoned management team.
Average Trading Volume: 10,723
Technical Sentiment Signal: Hold
Current Market Cap: C$162M
For a thorough assessment of HLS stock, go to TipRanks’ Stock Analysis page.